GLP1R and type 2 diabetes mellitus: Also, a recent study pulling out data from randomized controlled trials and a nationwide cohort concluded that dementia incidence was reduced in patients with type 2 diabetes treated with GLP1 receptor agonists (Nørgaard et al., 2022).